email   Email Us: info@lupinepublishers.com phone   Call Us: +1 (914) 407-6109   57 West 57th Street, 3rd floor, New York - NY 10019, USA

Lupine Publishers Group

Lupine Publishers

ISSN: 2637-4579

Open Access Journal of Biomedical Engineering and Biosciences

Mini Review(ISSN: 2637-4579)

Challenges in Integrative Research in Therapeutic and Diagnostic Proteins: Translation and Conformational Engineering

Volume 2 - Issue 3

Ajay K Ray*

  • Author Information Open or Close
    • Department of Chemical and Biochemical Engineering, University of Western Ontario, Canada

    *Corresponding author: Ajay K Ray, Department of Chemical and Biochemical Engineering, University of Western Ontario, Canada

Received: April 06, 2018;   Published: April 16, 2018

DOI: 10.32474/OAJBEB.2018.02.000138

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Biopharmaceuticals are mostly protein-derived medical drugs play vital roles in the human body catalyzing sequence of biochemical reactions. These biologics, which include therapeutic proteins, monoclonal antibodies (MAbs), vaccines, hormones, and fusion proteins, are used in the treatment, diagnosis and prevention of specific diseases such as cancer, multiple sclerosis, rheumatoid arthritis, diabetes, and a variety of cardiovascular diseases [1-3]. They are large molecular weight compounds with complex 3D structures mimicking molecules found in human bodies. Their production by living cells makes them different from classical small molecular weight chemical drugs (e.g., antibiotics) and in general, protein drug production by living cells is generally difficult [3]. With the advent of recombinant DNA technology, the post genomic era is seeing a massive increase in valuable protein products entering the clinical trials to manage disease with high specificity [4]. The global market for recombinant bio-pharmaceuticals has been growing rapidly from 30 products with a market value of USD $50-60 billion in 2004 to more than 151 unique products approved by the FDA by 2012 valued at USD $138 billion and is expected to surpass $320 billion by 2020.

Abbrevations: MAbs: Monoclonal Antibodies; CHO: Chinese Hamster Ovary; MCCSMB: Multiple Column Chromatography Based on Simulated Moving Bed Technology

Mini Review| References|

Close

Online Submission System

Drag and drop files here

or

Browse Files
( For multiple files submission, zip them in a single file to submit. For file zipping software Download )